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Introduction: In the phase III, LUX-Lung 6 trial, afatinib prolonged 
progression-free survival (PFS) versus cisplatin/gemcitabine in Asian 
patients with epidermal growth factor receptor (EGFR) mutation-
positive non–small-cell lung cancer (NSCLC). This article provides 
detailed assessments of patient-reported outcomes (PROs), a LUX-
Lung 6 secondary end point, and explores the relationship between 
PFS and health-related quality of life (QoL) in these patients.
Methods: Patients (n = 364) were randomized (2:1) to oral afatinib (40 mg/
day) or up to six cycles of cisplatin/gemcitabine (21-day cycle; cisplatin 
75 mg/m2 [d1]; gemcitabine 1000 mg/m2 [d1,8]). QoL was assessed using 
the European Organization for Research and Treatment of Cancer Quality 
of Life Questionnaire and its lung cancer-specific module. The relation-
ship between PFS (investigator assessment and independent review) and 
QoL was evaluated using analysis of covariance and a longitudinal model.
Results: More patients treated with afatinib versus cisplatin/gemcitabine 
showed improvements in global health status/QoL (p < 0.0001) and phys-
ical (p < 0.0001), role (p = 0.013), and social (p < 0.001) functioning 
scales. Delayed symptom deterioration and better QoL over time was also 
observed with afatinib. QoL measured before tumor assessment was con-
siderably poorer for patients with progression than those without progres-
sion, with significant differences in mean scores at multiple assessment 
time points. Results from the longitudinal analysis consistently demon-
strated a significant negative impact of progression on QoL (p < 0.0001).
Conclusion: Afatinib improved PFS and PROs versus chemother-
apy in EGFR mutation-positive NSCLC patients. Progression was 
associated with statistically significant worsening in QoL measured 
before tumor assessment, underscoring the value of PFS as a clini-
cally relevant end point.
Key Words: Afatinib, Non–small-cell lung cancer, Progression-free 
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Therapeutic inhibition of epidermal growth factor recep-tor (EGFR) signaling is an effective treatment option in 
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patients with EGFR mutation-positive non–small-cell lung 
cancer (NSCLC).1 Afatinib is an irreversible ErbB family 
blocker that inhibits signaling from all homodimers and het-
erodimers formed by ErbB family members (EGFR, human 
epidermal growth factor receptor 2 [HER2], ErbB3, and 
ErbB4).2,3 In two seminal phase III studies in patients with 
EGFR mutation-positive advanced NSCLC (LUX-Lung 3, 
afatinib versus cisplatin/pemetrexed in patients recruited 
globally; LUX-Lung 6, afatinib versus cisplatin/gemcitabine 
in Asian patients), first-line afatinib monotherapy (40 mg/
day, orally) significantly prolonged progression-free survival 
(PFS) compared with standard platinum-based chemotherapy 
regimens4,5; afatinib was consequently approved in this setting. 
In more recent analyses of these trials, afatinib was the first 
EGFR tyrosine kinase inhibitor to demonstrate an overall sur-
vival (OS) benefit over chemotherapy in patients with NSCLC 
harboring the EGFR Del19 mutation.6 Furthermore, afatinib 
has demonstrated clinical efficacy after progression on revers-
ible EGFR tyrosine kinase inhibitors, erlotinib and gefitinib.7,8
PFS offers practical advantages as a primary end point 
for clinical studies in patients with advanced cancers (e.g., 
faster trial completion and reporting of trial results, fewer 
patients, and lower costs).9 However, the clinical benefit of 
prolonged PFS should be substantiated with patient-reported 
outcome (PRO) data that reflect health-related quality of life 
(QoL), symptoms, and functional activity.9,10 Both LUX-
Lung 3 and 6 fully integrated comprehensive PRO evalua-
tion into outcome analyses, demonstrating improvements in 
lung cancer-related symptoms and QoL and a longer time to 
deterioration of these PROs.4,5,11,12 In the primary report of 
LUX-Lung 6, afatinib provided improvements in prespecified 
PROs focused on lung cancer-related symptoms of coughing, 
dyspnea, and pain.5 The current article expands on the pre-
vious report, providing additional data on prespecified lung 
cancer-related symptoms and evaluating whether improve-
ments in disease-related symptoms are accompanied by an 
improvement in global health status (GHS)/QoL and func-
tioning. Furthermore, although many state-of-the-art clinical 
studies in patients with NSCLC now include PRO measures,13 
the relationship between disease progression and QoL in these 
patients has rarely been analyzed. This analysis explores the 
relationship between PFS and QoL, evaluating the impact of 
tumor progression on QoL outcomes.
PATIENTS AND METHODS
Study Design and Patients
Details of the LUX-Lung 6 study design and patient 
eligibility criteria have been previously published.5 Briefly, 
this was a randomized, open-label, phase III study con-
ducted in China, Thailand, and South Korea. Patients were 
screened between April 2010 and November 2011. Eligible 
patients with EGFR mutation-positive stage IIIB (with pleu-
ral effusion) or stage IV lung adenocarcinoma were random-
ized (2:1) to oral afatinib 40 mg, once daily, or 1000 mg/m2 
gemcitabine followed by 75 mg/m2 cisplatin on day 1 and 
1000 mg/m2 gemcitabine on day 8 of each 21-day treatment 
cycle. The primary end point was PFS by independent central 
review, with PFS by investigator assessment defined as the 
main sensitivity analysis. Key secondary end points included 
objective tumor response, OS, adverse events (AEs), pharma-
cokinetics, and PRO.
This study was conducted in accordance with the 
Declaration of Helsinki, International Conference on 
Harmonization good clinical practice, local laws, and appli-
cable regulatory requirements and was approved by the insti-
tutional review board or independent ethics committee of each 
center. All patients provided written, informed consent for 
participation in the study.
Patient-Reported Outcomes Assessments
Patient-reported symptoms and QoL benefits were 
assessed using the multidimensional, cancer-specific, self-
administered European Organization for Research and 
Treatment of Cancer Quality of Life Questionnaire C30 
(EORTC QLQ-C30) and its lung cancer-specific module 
(QLQ-LC13).14,15 The QLQ-C30 comprises 30 questions across 
five functional scales (physical, role, cognitive, emotional, and 
social), three symptom scales (fatigue, pain, and nausea/vomit-
ing), a GHS/QoL scale, and various single items (e.g., dyspnea, 
diarrhea). The QLQ-LC13 comprises 13 questions across one 
multi-item scale to assess dyspnea and various other single 
items (e.g., chest pain, cough, sore mouth). Each of these ques-
tionnaires has been used routinely in previous studies, and addi-
tional details regarding the composition and application of the 
questionnaires have been previously published.5,11,16
PROs were assessed at randomization and every 3 weeks 
until disease progression or start of new cancer treatment. For 
chemotherapy patients, assessments occurred on day 1 of each 
treatment cycle and were delayed if the scheduled chemother-
apy was delayed. Patients completed the questionnaires at the 
clinic, before clinical assessment and treatment and before 
being provided with any test results. Compliance with PRO 
assessments was calculated per study visit as the number of 
completed questionnaires divided by the number of patients 
who had not yet progressed or started new cancer treatment.
Statistical Analyses
Questionnaire scales/items were scored according to 
EORTC published algorithms.17 For each scale or item, a lin-
ear transformation was applied to standardize the raw score to 
a range of 0 to 100. A 10-point change in score was considered 
clinically meaningful and was used to determine the propor-
tion of patients classified as improved (≥10-point increase for 
functioning scales; ≥10-point decrease for symptom scales/
items), stable, or worsened (≥10-point increase for symptom 
scales/items; ≥10-point decrease for functioning scales).18 
Proportions of patients with improved, stable, or worsened 
scores were summarized by treatment group, and a logistic 
regression model stratified by EGFR mutation type (Del19, 
L858R, or other) was used to compare the treatment arms.
Time to deterioration of a score (in months) was defined 
as the time from randomization to the first appearance of a 
score ≥10 points worse than baseline (≥10-point increase 
for symptom scales/items; ≥10-point decrease for function-
ing scales).18 Patients without post-baseline measurements 
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or without worsening were censored; those who died without 
documented worsening were considered to have deteriorated 
at the time of death. Time to deterioration was summarized as 
Kaplan–Meier plots, and a Cox proportional-hazards model 
(stratified by EGFR mutation type) was used to compare the 
treatment arms.
Changes in mean scores over time were assessed by 
longitudinal analysis with a mixed-effects growth curve 
model,19,20 allowing for within-patient assessment of changes, 
as previously described.11 Treatment effect was estimated 
as the average difference in mean scores between treatment 
arms. Analyses were repeated in subgroups defined by gen-
der, age (<65 vs. ≥65 years), Eastern Cooperative Oncology 
Group (ECOG) performance status (0 vs. 1), EGFR mutation 
type (Del19/L585R/other), and baseline symptoms (present 
vs. absent). To document the methodological robustness of the 
longitudinal analysis, which was conducted using a truncation 
point of 36 weeks (i.e., the median follow-up point in both 
treatment arms) with no data cutoff, sensitivity analyses were 
conducted that included a data cutoff point of 36 weeks and/
or shortening of the truncation point to 18 weeks. In addition, 
joint models that extended the mixed-effects model by includ-
ing nonrandom dropout mechanisms were used. Two dropout 
mechanisms were chosen: time to study completion and time 
to last PRO assessment.
As previously described by Griebsch et al.21 the rela-
tionship between tumor progression and QoL (based on the 
composite of QLQ-C30 questions 29 and 30) was evaluated 
in patients who completed a baseline QoL assessment and 
at least one measurement at the time of tumor progression 
(within a ±7-day interval). If a patient had more than one QoL 
assessment, the one closest to the actual tumor measurement 
date was used. Change from baseline in QoL score between 
patients with or without tumor progression was compared 
at each assessment time point (weeks 6, 12, 18, 24, 36, 42, 
and 48) using an analysis of covariance model, including 
covariates for baseline QoL score, progression, EGFR muta-
tion type, and randomized treatment; adjusted mean changes 
from baseline in QoL measures at each assessment time are 
reported. The effects of tumor progression on QoL over time 
were assessed using a longitudinal mixed-effects growth curve 
model, including the two random effects of intercept and slope 
(the week variable), terms for week, covariates related to pro-
gression status (based on either investigator assessment or 
independent review), and baseline covariates used for strati-
fication at randomization.19–21 No data cutoff was applied, but 
QoL data after the start of subsequent anticancer treatment 
following discontinuation of study medication was excluded.
RESULTS
Patient Population
Three hundred and sixty-four patients were randomized 
to receive afatinib (n = 242) or cisplatin/gemcitabine (n = 122). 
Patient characteristics were generally well balanced between 
the treatment groups and have been previously reported.5 
Briefly, median age was 58 years (range, 27–79 years), 65% of 
patients were female, 76% had an ECOG performance status 
of 1, and 77% had never smoked. The total number of patients 
who completed a baseline QoL assessment and at least one 
post-baseline QoL measurement and the progression status of 
patients based on investigator assessment at each study time 
point are shown in Figure 1.
Summary of Primary Efficacy
Detailed primary efficacy and safety findings for this 
patient population have been previously published.5 Median 
PFS based on independent review was significantly improved 
with afatinib (11.0 months) compared with cisplatin/gem-
citabine (5.6 months; hazard ratio [HR] = 0.28, p < 0.0001). 
This improvement in PFS was consistent with that observed 
with afatinib versus cisplatin/pemetrexed in the LUX-Lung 3 
study.4
Baseline Scores and Compliance
Mean (standard deviation; SD) baseline symptom scores 
in the afatinib arm were 37 (24) for cough, 25 (19) for dys-
pnea, and 24 (22) for pain; in the cisplatin/gemcitabine arm, 
mean (SD) baseline scores were 29 (26) for cough, 24 (21) for 
dyspnea, and 23 (23) for pain. Compliance rates for question-
naire completion on treatment were high for both the afatinib 
(96%) and cisplatin/gemcitabine (88%) arms. The most com-
mon reasons for noncompletion of PRO questionnaires were 
not related to health state.
Proportion of Patients with Improvements
Analysis of cough, dyspnea, and pain at the first occur-
rence of improvement or worsening from baseline was pre-
specified, and significant benefit of afatinib over cisplatin/
gemcitabine has been previously reported.5 A significantly 
greater percentage of patients treated with afatinib com-
pared with cisplatin/gemcitabine also showed improvements 
in GHS/QoL (p < 0.0001) and physical (p < 0.0001), role 
(p = 0.013), and social (p < 0.001) functioning scales (Fig. 2), 
and the symptom of fatigue (77.2% vs. 52.5%; p < 0.0001).
Time to Deterioration
Longer time to deterioration was observed with afa-
tinib compared with cisplatin/gemcitabine for the individual 
lung cancer-related symptoms of cough, dyspnea, and pain,5 
and for all functioning scales and the overall GHS/QoL score 
(Fig. 3).
Changes in Scores over Time
Improvements in mean scores were observed with afa-
tinib compared with cisplatin/gemcitabine for the individual 
lung cancer-related symptoms of cough, dyspnea, and pain.5 
Patients treated with afatinib versus cisplatin/gemcitabine also 
demonstrated better mean scores over time for all functioning 
scales, and the overall GHS/QoL score (Fig. 4).
Subgroup Analyses
Findings from subgroup analyses were largely con-
sistent with primary analysis results. Delay in time to dete-
rioration with afatinib over cisplatin/gemcitabine was more 
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pronounced in patients experiencing baseline symptoms ver-
sus asymptomatic patients for lung cancer-related symptoms 
(QLQ-LC13) of cough (HR = 0.38 vs. 1.05), dyspnea while 
walking (HR = 0.38 vs. 0.62), and pain in chest (HR = 0.33 
vs. 0.64), pain in arm/shoulder (HR = 0.27 vs. 0.77), and pain 
in other parts (HR = 0.47 vs. 1.17).
Sensitivity Analyses
For the analysis of differences in scores over time, sev-
eral sensitivity analyses of cough (see Supplemental Fig. 1, 
Supplemental Digital Content 1, http://links.lww.com/JTO/
A816, displaying sensitivity analyses for differences in mean 
scores for cough in the primary analysis and using additional 
data cut-offs and truncation points), dyspnea, and pain were 
conducted. For all three symptoms, differences in mean scores 
between afatinib and cisplatin/gemcitabine were similar to the 
primary analysis with all data cut-offs and truncation points 
analyzed, confirming robustness of the results. In addition, sen-
sitivity analyses using joint models based on different patient 
dropout events consistently showed slightly larger estimates 
FIGURE 1.  Flow chart of patients with disease progression based on investigator assessment at each study time point. At each 
assessment time point, patients who had died or were lost to follow-up since the previous assessment were excluded from the 
analysis. QoL, quality of life.
FIGURE 2.  Percentage of patients with improvements in EORTC QLQ-C30 scores. EORTC QLQ-C30, European Organization 
for Research and Treatment of Cancer Quality of Life Questionnaire C30; GHS/QoL, global health status/quality of life.
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of differences in mean scores favoring afatinib compared 
with cisplatin/gemcitabine for all three symptoms, suggesting 
that the results of the primary analysis were conservative (see 
Supplemental Fig. 2, Supplemental Digital Content 2, http://
links.lww.com/JTO/A817, displaying sensitivity analyses for 
differences in mean symptom scores for coughing, dyspnea, 
and pain in the primary analysis and based on different patient 
dropout events).
Relationship Between Tumor 
Progression and QoL
The effects of tumor progression on QoL over the 
48-week assessment period, in terms of adjusted mean changes 
from baseline in GHS/QoL, in patients with and without pro-
gression are shown in Figure 5 (based on investigator assess-
ment) and in Supplemental Figure 3 (Supplemental Digital 
Content 3, http://links.lww.com/JTO/A818, based on inde-
pendent central review). Patients with tumor progression con-
sistently experienced poorer QoL at the time of progression 
compared with patients without progression, with more pro-
nounced differences from baseline in mean QoL scores for 
patients progressing more rapidly. Furthermore, results from 
the longitudinal analysis showed that progression had a signifi-
cant negative impact on GHS/QoL score, with an effect size of 
–7.69 (95% confidence interval, –9.22 to –6.17; p < 0.0001), 
indicating a deterioration in QoL.
FIGURE 3.  Time to deterioration in GHS/QoL and functioning scores. EORTC QLQ-C30, European Organization for Research 
and Treatment of Cancer Quality of Life Questionnaire C30; GHS/QoL, global health status/quality of life; Q, question.
FIGURE 4.  Differences in mean scores over time for GHS/QoL and functioning scores. EORTC QLQ-C30, European 
Organization for Research and Treatment of Cancer Quality of Life Questionnaire C30; GHS/QoL, global health status/quality of 
life; Q, question.
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DISCUSSION
The overall clinical benefit of new therapies in the treat-
ment of patients with advanced cancers, such as NSCLC, 
requires rigorous assessment of tumor progression and 
PROs.9,22 Afatinib monotherapy has consistently provided 
similar improvements in PFS compared with standard chemo-
therapy regimens in clinical studies of patients with advanced 
NSCLC recruited globally and in Asia.4,5 Importantly, afa-
tinib treatment was associated with manageable AEs and low 
discontinuation rates because of treatment-related AEs.4,5 
Previously reported improvements in lung cancer-related 
symptoms and overall QoL with afatinib in patients with 
NSCLC further support the clinical benefit of afatinib treat-
ment with respect to PROs.4,5,11,12,16
In this study, afatinib provided significant improve-
ments compared with cisplatin/gemcitabine in GHS/QoL 
score, and physical, role, and social functioning scales, with a 
longer time to deterioration and better mean scores over time 
for all functioning and symptom scales. Afatinib also pro-
vided significant improvements in lung cancer-related symp-
toms of cough, dyspnea, and pain5; these improvements were 
most pronounced in patients experiencing baseline symptoms 
compared with asymptomatic patients. Overall, the improve-
ments in PROs reported with afatinib in this study are consis-
tent with those reported in the phase III LUX-Lung 3 study.11
In addition to the improvements in PROs, a relation-
ship between tumor progression and QoL was demonstrated 
in patients treated in the study. Of note, PROs were collected 
before clinical assessment and before patients were provided 
with any test results (e.g., progression status). In this study, 
tumor progression was accompanied by a statistically signifi-
cant worsening in QoL, which was more pronounced in those 
patients with rapidly progressing disease. Furthermore, the 
observed progression-related deterioration in QoL was con-
sidered to be clinically meaningful based on recently proposed 
thresholds for the interpretation of GHS/QoL scores.23 A simi-
lar analysis of progression effects on QoL was recently con-
ducted for the LUX-Lung 1 (afatinib vs. placebo in patients 
with advanced NSCLC after failure of erlotinib and/or 
gefitinib) and LUX-Lung 3 (afatinib vs. cisplatin/pemetrexed 
in patients with treatment-naive, EGFR mutation-positive, 
advanced NSCLC) trials.21 The results presented here are con-
sistent with the findings previously reported for these studies.
Overall, these results demonstrate the value of PFS as a 
clinically relevant end point associated with PROs in patients with 
advanced NSCLC. Furthermore, they provide support for the use 
of PRO measures in addition to PFS in the development of new 
treatments and as a consideration when choosing available treat-
ment options for patients in the clinic. These combined measures 
are particularly relevant for new therapies in the absence of OS 
data and in combination with traditional chemotherapy regimens 
that are not associated with improvements in PROs.
In summary, this report expands on the robust analyses 
to date showing improved PROs and prolonged PFS with the 
ErbB family blocker afatinib in patients with advanced EGFR 
mutation-positive NSCLC. Furthermore, tumor progression was 
associated with a significant, clinically meaningful deterioration 
in PROs at the time of progression. These findings confirm those 
from previous analyses of afatinib and demonstrate the value of 
PFS as a clinically relevant primary end point associated with 
improved PROs in patients with advanced NSCLC.
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